Chronic SSRI Treatment Exacerbates Serotonin Deficiency in Humanized Tph2 Mutant Mice
Citations Over Time
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are a major class of antidepressants that act by blocking inward transport of serotonin (5-HT) into presynaptic neurons mediated by the serotonin transporter (SERT). Both reuptake and ongoing synthesis are essential in supporting intraneuronal serotonin concentrations in serotonergic neurons. A rare mutation in tryptophan hydroxylase 2 (Tph2), the rate limiting enzyme for 5-HT synthesis, was identified in several patients with major depression, and knock-in mice expressing the analogous mutation (R439H Tph2 KI) show 80% reduction in 5-HT synthesis and tissue levels. Chronic treatment with SSRIs (fluoxetine and paroxetine) resulted in a dramatic further depletion of 5-HT tissue levels in R439H Tph2 KI mice (down to 1-3% of wild type levels) while having little effects in wild-type controls. Treatment with the 5-HT precursor 5-hydroxytryptophan (5-HTP) restored 5-HT tissue content in mutant mice, and cotreatment with 5-HTP and fluoxetine essentially prevented the depleting effect of a chronic SSRI. These data demonstrate that chronic SSRI treatment could further exacerbate the 5-HT deficiency in Tph2 mutation carriers, and this can be prevented by 5-HTP supplementation.
Related Papers
- → Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2(2005)79 cited
- → Functional promoter polymorphism of the neuronal isoform of tryptophan hydroxylase (Tph2) in suicide(2010)16 cited
- → Knockout Mouse Points to Second Form of Tryptophan Hydroxylase(2003)24 cited
- → Regional mRNA expression of a second tryptophan hydroxylase isoform in the human brain(2004)1 cited
- Visions & Reflections Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2(2006)